Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12239065 | 0.89 | PLAU (0.39) | PLAU | |
| SCHEMBL12238996 | 0.89 | PLAU (0.36) | PLAU | |
| SCHEMBL12215881 | 0.88 | ALDH1A1 (0.39) | PLAUMEN1KMT2ACYP2C9TSHR | |
| SCHEMBL12239199 | 0.86 | PLAU (0.35) | PLAU | |
| SCHEMBL12239014 | 0.85 | CYP3A4 (0.40) | MEN1KMT2ACYP2C9TSHRALDH1A1 | |
| SCHEMBL12238857 | 0.85 | L3MBTL1 (0.34) | PLAUMEN1KMT2A | |
| SCHEMBL12239807 | 0.84 | PLAU (0.34) | PLAUMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL12239007 | 0.84 | CRBN (0.38) | MEN1KMT2ACYP2C9TSHRALDH1A1 | |
| SCHEMBL12302393 | 0.83 | ACACB (0.33) | PLAUMEN1KMT2ACYP2C9HSD17B10 | |
| SCHEMBL12238775 | 0.83 | VNN1 (0.35) | PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039472-B2 | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |